Minerva Neurosciences reveals Q4 loss amid regulatory transition
Minerva Neurosciences (NASDAQ:NERV), a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, reported a net loss of $283.7 million for the fourth quarter ended December 31, 2025.











